New immunologic treatments for inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 16, Issue 6, 2000, Pages 565-570

  Heuschkel, R B ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ETANERCEPT; INFLIXIMAB; ISIS 2303; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENTERITIS; FEVER; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; NAUSEA; NONHUMAN; PNEUMONIA; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 0034438813     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200011000-00018     Document Type: Review

References (60)

1. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
2. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production
3. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
4. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects
5. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis
6. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-alpha (cA2) therapy
7. A major role for matrix metalloproteinases in T cell injury in the gut
8. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
9. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
10. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
11. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
12. Infliximab for the treatment of fistulas in patients with Crohn's disease
13. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: Report of two cases
14. IBD Highlights from the 1999 American College of Gastrolenterology Meeting: Infliximab and 6-MP
15. Treatment of severe esophageal Crohn's disease with infliximab
16. Successful management of Crohn's disease of the ileoanal pouch with infliximab
17. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC)
18. Review article: Safety of infliximab in clinical trials
19. Delayed hypersensitivity to infliximab (remicade) re-infusion after 2-4 year interval without treatment [abstract]
20. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease
21. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571
22. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumor necrosis factor alpha
23. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease
24. Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease
25. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
26. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease
27. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
28. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
29. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
30. Enbrel (etanercept): Prescribing information
31. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
32. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
33. Interleukin-10 gene knock-out mice: A model of chronic inflammation
34. Effects of single intravenous doses of recombinant human interleukin-10 on subsets of circulating leukocytes in humans
35. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group
36. Anti- and pro-inflammatory effects of interleukin-10 in mild to moderate Crohn's disease
37. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein
38. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease
39. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
40. A randomized, double-masked, placebo-controlled study of recombinant human interleukin eleven (rh/L-11) in Crohn's disease subjects not receiving prednisone
41. Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody
42. CD4 antibody treatment in patients with active Crohn's disease: A phase 1 dose finding study
43. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells
44. Randomised double-blind placebo-controlled trial of recombinant humanised antibody to a4 integrin (antegren) in active Crohn's disease
45. Treatment of active ulcerative colitis with a recombinant humanised antibody to a4 integrin (antegren) [abstract]
46. CD40L is important for induction of, but not response to, costimulatory activity, ICAM-1 as the second costimulatory molecule rapidly upregulated by CD40L
47. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis
48. Circulating soluble adhesion molecules in inflammatory bowel disease
49. Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence
50. Efficacy and safety of ISIS 2302 (ICAM antisense oligonucleotide) treatment of steroid dependent Crohn's disease
51. A metalloproteinase disintegrin that releases tumor-necrosis factor-alpha from cells
52. Structural features and biochemical properties of TNF-alpha converting enzyme (TAOE)
53. Role of NF-kappaB in immune and inflammatory responses in the gut
54. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
55. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis
56. Therapeutic antibodies elicited by immunization against TNF-alpha
57. Endoscopic and histologic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
58. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease
59. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis